The facts behind Reta
Retatrutide, often called “Reta,” is an investigational triple-agonist weight-loss drug. Early trials look impressive, but the main questions are long-term safety, tolerability, and what happens outside tightly run studies.
Tag
Clinical
Pages related to Clinical.
Tirzepatide
A long-acting, synthetic dual agonist of the GLP-1 and GIP receptors, used clinically for type 2 diabetes and obesity.
Gonadorelin
A synthetic form of gonadotropin-releasing hormone (GnRH), an upstream hypothalamic signal in the reproductive hormone axis.
Kisspeptin
A family of neuropeptides (KISS1-derived) that strongly stimulate the reproductive hormone axis upstream of GnRH, studied in reproductive physiology and clinical fertility contexts.
DOTATATE
A somatostatin receptor targeting peptide (octreotate derivative) used as the targeting component in peptide receptor radionuclide therapy (PRRT), including 177Lu-DOTATATE for neuroendocrine tumors.
Teduglutide
A GLP-2 analog peptide drug used in short bowel syndrome to improve intestinal absorption and reduce parenteral support needs in some patients.
Glucagon-like peptide-1 (GLP-1)
An endogenous gut hormone peptide that signals through the GLP-1 receptor and forms the biological basis for GLP-1 receptor agonist drugs used in diabetes and obesity.
GLP‑1 drugs and atrial fibrillation risk
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
GLP‑1 plus SGLT2 in fatty liver disease
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
How vosoritide looks after one year
A new meta-analysis pools one-year results for vosoritide in children with achondroplasia, clarifying typical growth changes and the most common side effects.
An umbrella review asks: do GLP‑1 drugs help heart failure?
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
GLP-1 drugs and depression: a meta-analysis finds a signal, but the heterogeneity is huge
An open-access meta-analysis reports higher odds of depression-related adverse events among GLP-1 receptor agonist users (OR 1.49), but between-study heterogeneity is extreme (I² ~99%), which limits how literally the pooled number should be taken.
SURPASS-CVOT post hoc: broader cardiorenal outcomes favor tirzepatide vs dulaglutide
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.
Do GLP‑1 drugs help heart failure symptoms?
A new randomized-trial meta-analysis (preprint) finds the ‘hard outcome’ signal in heart failure is not clean, but people with HFpEF and obesity report better symptoms and walk a bit farther on GLP‑1 drugs.
Pancreatitis fears and GLP‑1s: the cleanest data so far
A living meta-analysis of placebo-controlled RCTs of semaglutide and tirzepatide lands near ‘no signal’ for acute pancreatitis. That’s reassuring, but rare-event uncertainty is exactly why this concern keeps coming back.
Surgery still outperforms GLP‑1 drugs over longer follow-up
A meta-analysis comparing bariatric surgery with GLP‑1 drugs found the gap widened as follow-up got longer. The signal is strong, but still confounded by non-random treatment selection and real-world access differences.
For short bowel syndrome, GLP‑2 drugs work—and the side effects matter
A 2026 review of glucagon-like peptide therapies in short bowel syndrome puts the spotlight where patients live: side effects, monitoring, and the trade-offs that come with reducing dependence on IV nutrition.
Japan’s real-world 177Lu‑DOTATATE cohort gives PRRT a scale check
A nationwide multicenter retrospective study from Japan (422 patients, 33 institutions) reports real‑world outcomes for 177Lu‑DOTATATE PRRT in advanced neuroendocrine neoplasms. Response and progression-free survival look broadly consistent with PRRT’s established role, with useful predictor breakdowns.